<DOC>
	<DOC>NCT00454805</DOC>
	<brief_summary>The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.</brief_summary>
	<brief_title>AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Written informed consent Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease One or more evaluable lesions Prior hormonal therapy with fulvestrant More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer Prior biologic therapy for ABC including AntiVEGF agents Radiation therapy within 4 weeks prior to provision of consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>